Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-28
2006-02-28
Fay, Zohreh (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S408000, C514S913000
Reexamination Certificate
active
07005446
ABSTRACT:
Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed.
REFERENCES:
patent: 4565821 (1986-01-01), Chiou
patent: 5637610 (1997-06-01), Nakabayashi et al.
patent: 5981568 (1999-11-01), Kunz et al.
patent: WO 98/01137 (1998-01-01), None
Foletta et al., “Transcriptional regulation in the immune systems: all roads lead to AP-1,”Journal Leukocyte Biology.,vol. 63:139-152, 1998.
Karin et al., “AP-1 function and regulation,”Current. Opinion in Cell Biology,vol. 9:240-246, 1997.
Lee et al., “Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40,” Nature, vol. 325:368-372, (1987).
Whitmarsh et al., “Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways,” J. Mol. Med., vol. 74:589-607, 1996.
Ainbinder et al., “Regulatory mechanisms involved in activator-protein-1 (AP-1)-mediated activation of glutathione-S-transferase gene expression by chemical . . . ,” Eur. J. Biochem., vol. 243:49-57, 1997.
Xie et al., “ARE- and TRE-mediated regulation of gene expression,”Journal of Biological Chemistry,vol. 270(12):6894-6900, 1995.
Ainbinder et al., “Signaling pathways in the induction of c-fos and c-jun proto-oncogenes by 3-methylcholanthrene,”Receptors and Signal Transduction,vol. 7(4):279-289, 1997.
Oazki et al., “The comparative effects of haloperidol, (-)-sulpiride, and SCH23390 on c-fos and c-jun mRNA expressions, and AP-1 DNA binding . . . ,”Eur. Neuropsychopharmacol.,vol. 7:181-187, 1997.
Schreiber et al., “Rapid detection of octamer binding proteins with ‘mini-extracts’ prepared from a small number of cells,”Nucleic Acids Res.,vol. 17(15):6419, 1989.
Johnson et al., “Human trabecular meshwork organ culture: A new method,” Invest Ophthalmol & Vis Sci., vol. 28(6):945-953, 1987.
Erickson-Lamy et al., “Outflow facility studies in the perfused human ocular anterior segment,” Exp. Eye Res., vol. 52:723-731, 1991.
Clark et al., “Dexamethasone-induced ocular hypertension in perfusion cultured human eyes,”Invest. Ophthalmol. Vis. Sci.,vol. 36(2):478-489, 1995.
Weiner, A.L., “Polymeric Drug Delivery Systems For the Eye,”Polymeric Site-specific Pharmacotherapy,Ed., A.J. Domb, John Wiley & Sons, pp. 315-346, 1994.
Clark Abbot F.
Pang Iok-Hou
Shade Debra L.
Alcon Manufacturing Ltd.
Fay Zohreh
Schultz Teresa J.
Yeager Sally S.
LandOfFree
Use of AP-1 activators to treat glaucoma and ocular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of AP-1 activators to treat glaucoma and ocular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of AP-1 activators to treat glaucoma and ocular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3686111